Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Pelacarsen Initiation in Patients With Elevated Lp(a) and Recent Acute Coronary Syndrome
NCT07625306Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2026
- Primary completion
- Jan 2029
01
Overview
A Phase 3 trial of pelacarsen in acute coronary syndrome (ACS), sponsored by Novartis. Planned start Sep 2026; status: withdrawn.
02
Drugs
pelacarsen
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT07625306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625306.